22 hours Ago By ABMN Staff
Marshall Wace LLP increased its position in MaxCyte, Inc. ( NASDAQ:MXCT – Free Report ) by 13.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC.
The firm owned 252,333 shares of the company’s stock after purchasing an additional 29,739 shares during the quarter. Marshall Wace LLP’s holdings in MaxCyte were worth $1,050,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds also recently modified their holdings of MXCT.
Prudential Financial Inc. bought a new stake in shares of MaxCyte in the 4th quarter valued at about $65,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of MaxCyte in the 4th quarter valued at about $74,000.
China Universal Asset Management Co. Ltd. raised its holdings in shares of MaxCyte by 10.
7% in the 4th quarter. China Universal Asset Management Co. Ltd.
now owns 22,366 shares of the company’s stock valued at $93,000 after purchasing an additional 2,154 shares during the period. EntryPoint Capital LLC bought a new stake in shares of MaxCyte in the 4th quarter valued at about $185,000. Finally, SG Americas Securities LLC raised its holdings in shares of MaxCyte by 25.
9% in the 4th quarter. SG Americas Securities LLC now owns 47,805 shares of the company’s stock valued at $199,000 after purchasing an additional 9,836 shares during the period. 68.
81% of the stock is owned by institutional investors. Wall Street Analyst Weigh In MXCT has been the topic of a number of research reports. Stifel Nicolaus decreased their price target on shares of MaxCyte from $11.
00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, March 12th. BTIG Research set a $6.
00 price target on shares of MaxCyte and gave the company a “buy” rating in a research note on Wednesday, March 12th. MaxCyte Stock Performance Shares of MXCT opened at $2.91 on Wednesday.
MaxCyte, Inc. has a 52 week low of $2.21 and a 52 week high of $5.
26. The firm has a market cap of $309.37 million, a P/E ratio of -8.
56 and a beta of 1.39. The firm’s 50-day simple moving average is $2.
98 and its 200 day simple moving average is $3.68. MaxCyte Company Profile ( Free Report ) MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. Featured Articles Want to see what other hedge funds are holding MXCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MaxCyte, Inc.
( NASDAQ:MXCT – Free Report ). Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter .
.
